ACADIA Pharmaceuticals Inc. presented updates on its commercial performance and pipeline development at the Jefferies London Healthcare Conference. The company reported continued growth of its core franchise product, NUPLAZID, with third-quarter net sales reaching $177.5 million, a 12% increase year-over-year. Referrals and new prescriptions for NUPLAZID also saw year-over-year growth of 21% and 23%, respectively. Strategic investments in 2026 will include a 30% increase in customer-facing roles and a focus on newly diagnosed patients and physicians. The pipeline portfolio highlighted late- and early-stage candidates targeting neurological and rare diseases, including Alzheimer's disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor, tardive dyskinesia, Rett/Fragile X, Huntington's disease, and SYNGAP1. Several clinical trial milestones are anticipated through 2026 and 2027, including Phase 2 and Phase 3 study initiations and readouts. The company estimates the full potential peak sales for its pipeline products at $11 billion, assuming successful approval and commercialization. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.
Comments